COMMUNIQUÉS West-GlobeNewswire
-
Gelteq Announces Positive Preclinical Results Demonstrating Enhanced Bioavailability Using Its Proprietary Gel-Based Drug Delivery Platform
24/11/2025 -
Menarini Group Announces New Data on ELZONRIS® (tagraxofusp-erzs) to be Presented at the 67th American Society of Hematology Annual Meeting and Exposition
24/11/2025 -
CytoDyn to Present Prolonged Survival Data on Leronlimab in Metastatic Triple-Negative Breast Cancer at the San Antonio Breast Cancer Symposium
24/11/2025 -
Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs
24/11/2025 -
Biotech Valuations Rise as New Clinical Platforms Show Progress
24/11/2025 -
Imviva Biotech Announces Seven Presentations Highlighting its ANSWER™ Allogeneic CAR-T Platform at the 67th American Society of Hematology Annual Meeting
24/11/2025 -
Biodexa Activates First European Site for Registrational Phase 3 Serenta Trial in FAP
24/11/2025 -
Profusa to Present Late Breaking U.S.-Based Clinical Trial Update at Paris Vascular Insights 2025
24/11/2025 -
BioCardia Strengthens Leadership Team with The Addition of Farhan Shahab as Vice President of Quality
24/11/2025 -
Nanox.AI Bone Solutions, Advanced AI-Powered Software for Spine Assessment, Recommended by NICE for Early Value Assessment in UK National Health Service hospitals
24/11/2025 -
Catalyst Pharmaceuticals to Participate in the Bank of America CNS Therapeutics Virtual Conference
24/11/2025 -
Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk Populations
24/11/2025 -
HealthLynked Engages NE Holdings, LLC to Lead Strategic Advisory Services for Nasdaq Listing
24/11/2025 -
LB Pharmaceuticals Announces Presentation at the Piper Sandler 37th Annual Healthcare Conference
24/11/2025 -
Day One Announces Three Year Follow-Up Data From OJEMDA™ (tovorafenib) Phase 2 FIREFLY-1 Trial at the 2025 Society for Neuro-Oncology (SNO) Annual Meeting
24/11/2025 -
LifeMD Recognized by the 2025 Deloitte Technology Fast 500™ and by TIME’s America’s Growth Leaders of 2026
24/11/2025 -
Enlivex Announces $212,000,000 Private Placement to Initiate World’s First Prediction Markets Digital Asset Treasury Strategy, via RAIN token Accumulation, and the Appointment of Matteo Renzi, Former Prime Minister of Italy, to its Board
24/11/2025 -
Prenetics Executives Announce Open Market Share Purchases Totaling Approx. $1.45 Million
24/11/2025 -
Adaptive Biotechnologies Announces Nearly 90 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 67th ASH Annual Meeting
24/11/2025
Pages